Cellestis is on the brink of generating substantial profits from its revolutionary Tuberculosis (TB) diagnostic, Quantiferon TB Gold (QFTG). The Company has a massive market, high profit margin and a global monopoly with patent protection to 2017 and possibly 2021, on the world’s leading infectious killer disease. And it has tremendous “blue sky” potential for other new diagnostics.
With a staggering one-third of the world’s population infected, TB is responsible for nine million new cases and more than two million deaths annually, mostly in developing countries. The World Health Organisation has declared TB a global emergency, the only disease for which this has been done. TB is spread through the air like a common cold and a person only needs to inhale a small amount to become infected. Multi-Drug Resistant TB is making TB even more deadly. The tragedy of TB is that most deaths are preventable through drug therapy. However, up until the discovery of QFTG the world has lacked an adequate TB diagnostic.
3. What the world’s leading TB authorities are saying about QFTG. (Our bolding)
“QFTG is positioned to revolutionize how TB infection is diagnosed.”
- Dr Gerald Mazurek - US Centers for Disease Control and Prevention (CDC) - 09/12/2005
“The Quantiferon test is likely to revolutionize testing for latent TB infection, and alter our understanding of the risk of TB infection once it is in wider use.” - American Thoracic Society (ATS) - February 2005
“This test is a huge deal ..... It really is a paradigm shift ..... This test has profound public health implications.”
- Health Commission, City & County of San Francisco - December 2005
“The NTCA strongly advocates the use of FDA-approved in vitro diagnostic tests [Quantiferon] to diagnose latent TB infection .....Blood assays done in vitro are likely to become the test of choice for most or all populations in the future.”
- US National TB Controllers Association (NTCA) - January 2005
“This test will be widely used in the near future.”
- Dr Toru Mori, Director Research Institute, Japan Anti- Tuberculosis Association (JATA) - March 2004 - Former Director World Health Organisation Research Institute for Tuberculosis (WHO)
“I suspect it will be recommended in place of a tuberculin skin test ..... Its use is likely to be taken up quickly.”
- Professor R.E. Chaisson Director Johns Hopkins University Centre for Tuberculosis Research - February 2005 and July 2005
CST Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
